Hitachi High-Tech Participates in OmniSeq Series B and Secures Japanese Distribution Rights
BUFFALO, NEW YORK – April 12, 2018 – OmniSeq® , a molecular diagnostics subsidiary of the Roswell Park Comprehensive Cancer Center, announced today Hitachi High-Technologies Corporation (TOKYO: 8036, Hitachi High-Tech)’s participation in OmniSeq’s Series B financing...OmniSeq & LabCorp Launch Tumor-Only MSI NGS Assay
BUFFALO, NEW YORK – April 16, 2018 – OmniSeq®, a molecular diagnostics subsidiary of the Roswell Park Comprehensive Cancer Center, and LabCorp® (NYSE: LH), a leading global life sciences company, announced today the commercial launch of OmniSeq MSI NGS, a tumor-only,...OmniSeq Receives CAP Accreditation and Publishes Analytical Validation Paper
Important Achievements Validate OmniSeq’s High Quality Laboratory Practices and Immune Report Card Assay Buffalo, NY – NOVEMBER 9, 2017 – OmniSeq, Inc., a molecular diagnostics subsidiary of the Roswell Park Cancer Institute, announced today that it received...OmniSeq and LabCorp Sign Exclusive Distribution Agreement and Series B Funding Commitment
Marcia Eisenberg, Chief Scientific Officer of LabCorp Diagnostics, to Join OmniSeq’s Board of Directors BUFFALO, N.Y., Aug. 21, 2017 (GLOBE NEWSWIRE) — OmniSeq, Inc., a molecular diagnostics subsidiary of the Roswell Park Cancer Institute, announced today that...Launch of Immune Report Card
BUFFALO, N.Y., June 14, 2017 (GLOBE NEWSWIRE) — OmniSeq, an innovation of Roswell Park Cancer Institute, announced today the commercial launch of Immune Report Card SM, the first immune profiling test designed to help oncologists select the best mono and...
Follow Us on Twitter
OmniSeq Advance "All I Want": https://t.co/NwtMmpXspL via @YouTube
Excellent work being done at UCSD by @Dr_R_Kurzrock to incorporate transcriptomics and clinical trial matching!
"I’m not saying that on the basis of this one trial transcriptomics can become standard of care but the #WINTHER trial definitely suggests transcriptomics should be an important part of additional clinical trials" @Dr_R_Kurzrock
@WIN_Consortium #ASCO18 https://t.co/GSJ7pbu2Cq